2 results
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
March 31, 2024 | December 31, 2023 | ||||||
(In thousands of USD) | |||||||
Assets | |||||||
Current assets: | |||||||
Cash | 481,147 | 340,450 | |||||
Prepayments and other receivables | 6,675 | 6,341 | |||||
Total current assets | 487,822 | 346,791 | |||||
Property, plant and equipment, net | 101 | 46 | |||||
Operating right of use asset | 38 | 55 | |||||
Intangible assets | 486 | 170 | |||||
Long term prepaid expenses | 16 | 35 | |||||
Total assets | 488,463 | 347,097 | |||||
Liabilities and Shareholders' Equity | |||||||
Current liabilities: | |||||||
Accounts payable | 8,536 | 16,923 | |||||
Accrued expenses and other current liabilities | 9,970 | 11,398 | |||||
Deferred revenue, current | 8,116 | 8,942 | |||||
Lease liability, current | 43 | 60 | |||||
Derivative warrant liabilities | 33,061 | 12,574 | |||||
Total current liabilities | 59,726 | 49,897 | |||||
Deferred revenue, net of current portion | 444 | 1,019 | |||||
Derivative earnout liability | 16,490 | 7,788 | |||||
Total liabilities | 76,660 | 58,704 | |||||
Commitments and contingencies (Note 10) | |||||||
Shareholders' Equity (deficit): | |||||||
Ordinary shares, €0.12 par value; 400,000,000 shares authorized; 89,720,836 and 82,469,768 shares issued and outstanding as at March 31, 2024 and December 31, 2023, respectively | 11,113 | 10,173 | |||||
Additional paid-in capital | 807,008 | 590,771 | |||||
Accumulated loss | (410,740) | (316,973) | |||||
Accumulated other comprehensive income (loss) | 4,422 | 4,422 | |||||
Total shareholders' equity | 411,803 | 288,393 | |||||
Total liabilities and shareholders' equity (deficit) | 488,463 | 347,097 |
10-K
2023 FY
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Annual report
8:00am
As at December 31, | |||||||
2023 | 2022 | ||||||
(In thousands of USD) | |||||||
Assets | |||||||
Current assets: | |||||||
Cash | 340,450 | 467,728 | |||||
Prepayments and other receivables | 6,341 | 10,251 | |||||
Total current assets | 346,791 | 477,979 | |||||
Property, plant and equipment, net | 46 | 34 | |||||
Operating right of use asset | 55 | 120 | |||||
Intangible assets | 170 | 208 | |||||
Long term prepaid expenses | 35 | 156 | |||||
Total assets | 347,097 | 478,497 | |||||
Liabilities and Shareholders' Equity | |||||||
Current liabilities: | |||||||
Accounts payable | 16,923 | 11,853 | |||||
Accrued expenses and other current liabilities | 11,398 | 6,117 | |||||
Deferred revenue, current | 8,942 | 13,874 | |||||
Lease liability, current | 60 | 66 | |||||
Derivative warrant liabilities | 12,574 | 4,147 | |||||
Total current liabilities | 49,897 | 36,057 | |||||
Deferred revenue, net of current portion | 1,019 | 4,792 | |||||
Lease liability, net of current portion | - | 60 | |||||
Derivative earnout liability | 7,788 | 7,522 | |||||
Total liabilities | 58,704 | 48,431 | |||||
Commitments and contingencies (Note 13) | |||||||
Shareholders' Equity (deficit): | |||||||
Ordinary shares, €0.12 par value; 400,000,000 shares authorized; 82,469,768 and 81,559,780 shares issued and outstanding at December 31, 2023 and 2022, respectively | 10,173 | 10,055 | |||||
Additional paid-in capital | 590,771 | 555,625 | |||||
Accumulated loss | (316,973) | (140,036) | |||||
Accumulated other comprehensive income (loss) | 4,422 | 4,422 | |||||
Total shareholders' equity | 288,393 | 430,066 | |||||
Total liabilities and shareholders' equity (deficit) | 347,097 | 478,497 |
- Prev
- 1
- Next